,
Nash, Peter
Mease, Philip J.
McInnes, Iain B.
Rahman, Proton
Ritchlin, Christopher T.
Blanco, Ricardo
Dokoupilova, Eva
Andersson, Mats
Kajekar, Radhika
Mpofu, Shephard
Pricop, Luminita
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 12 December 2017
Accepted: 21 February 2018
First Online: 15 March 2018
Ethics approval and consent to participate
: The study was conducted in accordance with the principles of the Declaration of Helsinki. The institutional review board at each participating center approved the protocol. Further information related to ethics approval can be found online (). All centers received approval from independent ethics committees (IECs) or institutional review boards (IRBs). The names of IECs or IRBs that approved the study and the associated approval numbers where applicable are presented in Additional file: Table S1. Patients provided written informed consent before starting the study-related procedures.
: Not applicable.
: PN has received research grants for clinical trials and honoraria for lectures and advice from Novartis, AbbVie, Roche, Pfizer, BMS, Janssen, and Celgene. PJM has received grant/research support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB; been a consultant for AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB; and on the speakers’ bureau for AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB. IBM has received research grants, consultation fees, or speaker honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer and Roche; and been a consultant for pharmaceutical companies dealing with biologic agents in rheumatology. CTR has received research grants, consultation fees, or speaker honoraria from Amgen, UCB, AbbVie, Novartis, and Janssen. RB has received research grants from AbbVie, MSD, and Roche; consulting fees from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD; and was on the speakers’ bureau for AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD. ED has no competing interests. MA, RK, SM, and LP are employees of Novartis. RK, SM, and LP own Novartis stock.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.